Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410957 | 0.93 | FPR2 (0.42) | FPR2USP30TP53BACE1SMARCA2 | |
| SCHEMBL4408792 | 0.89 | TP53 (0.46) | USP30TP53SMARCA2SMARCA4PBRM1 | |
| SCHEMBL4415810 | 0.88 | USP30 (0.42) | USP30TP53SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30834657 | 0.88 | USP30 (0.42) | FPR2USP30BACE1SMARCA2SMARCA4 | |
| SCHEMBL30834647 | 0.88 | USP30 (0.42) | FPR2USP30BACE1SMARCA2SMARCA4 | |
| SCHEMBL30834655 | 0.88 | USP30 (0.42) | FPR2USP30BACE1SMARCA2SMARCA4 | |
| SCHEMBL4408213 | 0.86 | USP30 (0.43) | USP30TP53SMARCA2SMARCA4PBRM1 | |
| SCHEMBL31582194 | 0.85 | USP30 (0.42) | FPR2USP30BACE1SMARCA2SMARCA4 | |
| SCHEMBL4410166 | 0.85 | USP30 (0.51) | USP30BACE1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL24558178 | 0.85 | USP30 (0.39) | FPR2USP30TP53SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | FPR2 501/4885USP30 4369/4885TP53 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.